FIT-IG Trademark

Trademark Overview

On Wednesday, December 14, 2016, a trademark application was filed for FIT-IG with the United States Patent and Trademark Office. The USPTO has given the FIT-IG trademark a serial number of 87268386. The federal status of this trademark filing is CANCELLED - SECTION 8 as of Friday, March 14, 2025. This trademark is owned by EPIMAB BIOTHERAPEUTICS INC.. The FIT-IG trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Biotechnology research and analysis; scientific research and development; scientific research and development in the field of immunization and antibody screening; custom design and development of monoclonal antibodies
fit-ig

General Information

Serial Number87268386
Word MarkFIT-IG
Filing DateWednesday, December 14, 2016
Status710 - CANCELLED - SECTION 8
Status DateFriday, March 14, 2025
Registration Number5551511
Registration DateTuesday, August 28, 2018
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 25, 2017

Trademark Statements

Pseudo MarkFABS IN TANDEM IMMUNOGLOBULIN
Goods and ServicesBiotechnology research and analysis; scientific research and development; scientific research and development in the field of immunization and antibody screening; custom design and development of monoclonal antibodies

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, March 14, 2025
Primary Code042
First Use Anywhere DateSaturday, September 30, 2017
First Use In Commerce DateSaturday, September 30, 2017

Trademark Owner History

Party NameEPIMAB BIOTHERAPEUTICS INC.
Party Type30 - Original Registrant
Legal Entity Type11 - Company
AddressShanghai 201112
CN
Party NameEPIMAB BIOTHERAPEUTICS INC.
Party Type20 - Owner at Publication
Legal Entity Type11 - Company
AddressShanghai 201112
CN
Party NameEPIMAB BIOTHERAPEUTICS INC.
Party Type10 - Original Applicant
Legal Entity Type11 - Company
AddressShanghai 201112
CN

Trademark Events

Event DateEvent Description
Wednesday, June 21, 2017NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Saturday, December 17, 2016NEW APPLICATION ENTERED
Tuesday, December 20, 2016NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, March 16, 2017ASSIGNED TO EXAMINER
Thursday, March 16, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, April 5, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 25, 2017PUBLISHED FOR OPPOSITION
Tuesday, April 25, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, January 10, 2018NON-FINAL ACTION E-MAILED
Monday, December 18, 2017SOU TEAS EXTENSION RECEIVED
Monday, December 18, 2017SOU EXTENSION 1 FILED
Monday, December 18, 2017SOU EXTENSION 1 GRANTED
Wednesday, December 20, 2017NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, December 21, 2017TEAS STATEMENT OF USE RECEIVED
Thursday, December 21, 2017USE AMENDMENT FILED
Wednesday, January 10, 2018STATEMENT OF USE PROCESSING COMPLETE
Wednesday, January 10, 2018CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, January 10, 2018SU - NON-FINAL ACTION - WRITTEN
Wednesday, January 10, 2018NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, July 9, 2018TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, August 28, 2018REGISTERED-PRINCIPAL REGISTER
Monday, August 28, 2023COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Friday, March 14, 2025CANCELLED SEC. 8 (6-YR)
Tuesday, July 24, 2018NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Thursday, July 19, 2018ASSIGNED TO LIE
Friday, July 20, 2018CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, July 20, 2018TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, July 23, 2018ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED

Related Keywords

research development scientific custom design monoclonal antibodies screening immunization analysis